Skip to content

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.: 10-Q filed 2023-11-14

What THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. reported in its quarterly report filed 2023-11-14 (fiscal Q3 2023): 50 published measures, 134 facts as tagged in accession 0001493152-23-040890.

This filing

Form
10-Q (quarterly report)
Filed
2023-11-14
Fiscal period
fiscal Q3 2023
Accession
0001493152-23-040890 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-09-303,474,377USD
At 2022-12-313,605,531USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-09-302,165,081USD
At 2022-12-312,220,744USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-09-301,310,968USD
At 2022-12-311,384,787USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-09-3090,138USD
At 2022-12-3118,040USD
At 2022-09-3094,246USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-602,041USD92
2023-01-01 to 2023-09-30-1,742,322USD273
2007-08-06 to 2023-09-30-19,400,000USD5900
2022-07-01 to 2022-09-30-946,462USD92
2022-01-01 to 2022-09-30-2,738,142USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-09-30-849,263USD273
2022-01-01 to 2022-09-30-653,242USD273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2023-07-01 to 2023-09-3025,730USD92
2023-01-01 to 2023-09-3075,161USD273
2022-07-01 to 2022-09-3074,541USD92
2022-01-01 to 2022-09-30198,188USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-09-30930,023USD273
2022-01-01 to 2022-09-30854,232USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-01-01 to 2023-09-30-19,665USD273
2022-01-01 to 2022-09-30-200,000USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-09-30-19,414,380USD
At 2022-12-31-17,672,058USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-07-01 to 2023-09-303,286,909,395shares92
2023-01-01 to 2023-09-302,987,459,958shares273
2022-07-01 to 2022-09-302,565,663,048shares92
2022-01-01 to 2022-09-302,501,116,667shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-07-01 to 2023-09-303,286,909,395shares92
2023-01-01 to 2023-09-302,987,459,958shares273
2022-07-01 to 2022-09-302,565,663,048shares92
2022-01-01 to 2022-09-302,501,116,667shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-07-01 to 2023-09-300USD/shares92
2023-01-01 to 2023-09-300USD/shares273
2022-07-01 to 2022-09-300USD/shares92
2022-01-01 to 2022-09-300USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-07-01 to 2023-09-300USD/shares92
2023-01-01 to 2023-09-300USD/shares273
2022-07-01 to 2022-09-300USD/shares92
2022-01-01 to 2022-09-300USD/shares273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2023-01-01 to 2023-09-30800USD273
2022-07-01 to 2022-09-30800USD92
2022-01-01 to 2022-09-30800USD273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2023-09-30377,076USD
At 2022-12-31273,078USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2022-01-01 to 2022-09-30311,078USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-457,335USD92
2023-01-01 to 2023-09-30-1,429,708USD273
2022-07-01 to 2022-09-30-719,219USD92
2022-01-01 to 2022-09-30-2,321,301USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-09-30180,981USD
At 2022-12-31309,221USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2023-07-01 to 2023-09-3083,062USD92
2023-01-01 to 2023-09-30327,135USD273
2022-07-01 to 2022-09-30167,371USD92
2022-01-01 to 2022-09-30512,761USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-09-302,053,239USD
At 2022-12-312,210,237USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2023-09-302,780,379USD
At 2022-12-313,002,960USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2023-09-3021,764USD
At 2022-12-3125,398USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-07-01 to 2023-09-30476,013USD92
2023-01-01 to 2023-09-301,478,652USD273
2022-07-01 to 2022-09-30784,970USD92
2022-01-01 to 2022-09-302,486,052USD273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2023-09-3026,418USD
At 2022-12-3142,428USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2023-07-01 to 2023-09-3018,678USD92
2023-01-01 to 2023-09-3048,944USD273
2022-07-01 to 2022-09-3065,751USD92
2022-01-01 to 2022-09-30164,751USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-07-01 to 2023-09-30148,879USD92
2023-01-01 to 2023-09-30410,146USD273
2022-07-01 to 2022-09-30275,071USD92
2022-01-01 to 2022-09-301,177,123USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-09-303,450,665,355shares
At 2022-12-312,617,390,830shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-09-3090,138USD
At 2022-09-30105,249USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-09-3017,282,608USD
At 2022-12-3116,334,129USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2023-09-301,309,296USD
At 2023-06-301,491,152USD
At 2022-12-311,384,787USD
At 2022-09-301,783,675USD
At 2022-06-302,212,440USD
At 2021-12-31-804,982USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2023-09-30131,818USD
At 2022-12-318,612USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2023-09-30131,818USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2023-09-30413,517USD
At 2022-12-31301,359USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2023-09-3036,441USD
At 2022-12-3128,281USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2023-09-302,784,502USD
At 2022-12-313,014,620USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2023-09-30601,446USD
At 2022-12-31531,783USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2023-09-3042,661USD
At 2022-12-31212,352USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-602,857USD92
2023-01-01 to 2023-09-30-1,743,194USD273
2022-07-01 to 2022-09-30-945,662USD92
2022-01-01 to 2022-09-30-2,737,342USD273

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-602,857USD92
2023-01-01 to 2023-09-30-1,743,994USD273
2022-07-01 to 2022-09-30-946,462USD92
2022-01-01 to 2022-09-30-2,738,142USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-07-01 to 2023-09-30127,204USD92
2023-01-01 to 2023-09-30359,948USD273
2022-07-01 to 2022-09-30204,838USD92
2022-01-01 to 2022-09-30388,561USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2023-01-01 to 2023-09-308,161USD273
2022-01-01 to 2022-09-303,489USD273

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2023-01-01 to 2023-09-30222,581USD273
2022-01-01 to 2022-09-30191,192USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-145,522USD92
2023-01-01 to 2023-09-30-313,486USD273
2022-07-01 to 2022-09-30-226,443USD92
2022-01-01 to 2022-09-30-416,041USD273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2023-01-01 to 2023-09-302,475USD273
2022-01-01 to 2022-09-302,357USD273

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2022-01-01 to 2022-09-30800USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2023-01-01 to 2023-09-30677,378USD273
2022-01-01 to 2022-09-30445,000USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-09-30-3,634USD273
2022-01-01 to 2022-09-3025,769USD273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-09-30-16,010USD273
2022-01-01 to 2022-09-305,126USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-09-30-27,535USD273
2022-01-01 to 2022-09-30-30,051USD273

Inspect the source

Entity
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. / CIK 0001419051
Captured
2026-09-21T17:19:45.690Z
SEC response SHA-256
ad44380627053f8e0101ecf19c259e20a0a85d4c20ee53d5400d9dcf00541fc2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001419051.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))